Hypothesis

Intermittent dosing of dasatinib + quercetin (D+Q) combined with a low‑dose JAK1/2 inhibitor reduces senescent cell burden without inducing senescence‑like chromatin changes in non‑target tissues.

Rationale

Recent work shows that repeated D+Q courses can provoke senescence‑like chromatin alterations even in young cells, raising safety concerns for chronic use [6]. Conversely, JAK‑STAT signaling is a core driver of the SASP, and JAK inhibition attenuates SASP‑mediated inflammation without directly killing senescent cells [2][5]. By pairing intermittent senolysis with transient JAK blockade, we hypothesize that the senolytic pulse clears p16^high^ cells while the JAK inhibitor suppresses residual SASP from any surviving senescent cells, thereby preventing the paracrine induction of chromatin changes in neighboring cells.

Predictions

1. In diabetic kidney disease mouse models, intermittent D+Q (3 days on/4 days off) plus low‑dose ruxolitinib will lower renal p16^Ink4a^ and p21^Cip1^ mRNA levels to a greater extent than D+Q alone [2][3].
2. The combination will not increase H3K9me3 or DNMT3A expression in cortical tubular cells, markers associated with off‑target chromatin remodeling [6].
3. SASP cytokines (IL‑6, IL‑1α, MMP‑9) in serum and kidney homogenates will be significantly reduced relative to D+Q monotherapy, reflecting both senescent cell removal and SASP suppression [2][5].
4. Functional readouts (glomerular filtration rate, albuminuria) will improve comparably to D+Q alone, demonstrating that efficacy is not sacrificed.

Experimental Design

• Groups (n=10 per group): vehicle, intermittent D+Q alone, low‑dose ruxolitinib alone, intermittent D+Q + ruxolitinib.
• Duration: 8 weeks, with D+Q administered on days 1‑3 of each week; ruxolitinib given daily at 5 mg/kg (dose shown to inhibit JAK signaling without hematopoietic toxicity).
• Endpoints: qPCR for p16^Ink4a^ and p21^Cip1^, Western blot for H3K9me3 and DNMT3A, ELISA for SASP factors, in vivo renal function assays, histology for SA‑β‑gal.
• Statistical analysis: One‑way ANOVA with Tukey post‑hoc; significance set at p<0.05.

Falsifiability

If the combination does not achieve a greater reduction in senescent markers than D+Q alone, or if H3K9me3/DNMT3A levels rise indicating chromatin disruption, the hypothesis is falsified. Conversely, a clear improvement in both senescent burden and chromatin integrity would support the mechanistic synergy between intermittent senolysis and JAK‑mediated SASP dampening.